Table 1A.

Baseline characteristics of patients in Mortality_digHR-NS group and Mortality_digHR>1 group.

	Mortality digHR-NS, n=6818			MortalitydigHR>1, n=938
	Digoxin (n=3400)	Placebo (n=3418)	p value	Digoxin (n=470)	Placebo (n=468)	p value
Continuous/ordinal variables (mean±SD)
Age (yrs)	63±11	63±11	0.61	68±9	68±9	0.69
NYHA class	2.2±0.7	2.2±0.7	0.97	2.2±0.7	2.2±0.7	1.0
SBP (mmHg)	124±17	124±17	0.42	148±17	147±18	0.62
Heart rate (bpm)	78±13	78±13	0.07	83±13	83±12	0.79
BMI	27.0±5.2	27.2±5.2	0.05	28±6	29±6	0.67
Cardiothoracic ratio	0.5±0.07	0.5±0.07	0.93	0.5±0.08	0.5±0.08	0.88
EF (%)	31±12	31±12	0.57	40±15	40±15	0.79
Creatinine (mg/dl)	1.3±0.4	1.3±0.4	0.53	1.3±0.4	1.3±0.5	0.65
Categorical variables (%)
Females	20	20	1	58	58	1.0
Race (Caucasians)	86	86	0.63	84	84	0.86
DM	25	25	0.98	54	59	0.09
Hypertension	43	43	0.86	76	75	0.82
Ischemic etiology	70	69	0.56	65	67	0.54
Limitation-activity	75	76	0.61	77	77	0.94
Peripheral edema	21	21	1	22	19	0.22
S3	26	23	0.02	20	20	0.87
X-ray congestion	14	14	0.84	16	14	0.65
ACE inhibitor use	93	94	0.22	92	92	0.63
Diuretic use	77	77	0.75	83	85	0.42
Potassium sparing diuretic use	7	9	0.02	7	6	0.35

BMI: body mass index; DM: diabetes mellitus; EF: ejection fraction; Mortality_digHR-NS: group with non-significant association of digoxin use with all cause mortality; Mortality_digHR>1: group with increase in all cause mortality with use of digoxin; S3: third heart sound; SBP: systolic blood pressure.